Havencrest Capital Management, a private equity fund manager specializing in the healthcare industry, agreed to acquire a majority stake in Tekton Research, a clinical research facility that offers clinical trials, and device studies for pharma and medical device companies. Financial terms were not disclosed. "Tekton strives to be at the forefront of clinical research. Through our partnership with Havencrest, we intend to expand our network of talented investigators, improve clinical trial access for underrepresented patient communities and continue delivering high-quality data to our valued clients," Kip McKenzie, Tekton Founder and CEO.